Andreea Casian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andreea Casian has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Bogdan Tigu
Department of Personalized Medicine and Rare Diseases, MEDFUTURE—Institute for Biomedical Research, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
1 shared publication - Ciprian Tomuleasa
Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy
1 shared publication Cristina Dudnic
Department of Hematology, Public Medical Sanitary Institution (PMSI) Institute of Oncology, Chisinau, Republic of Moldova
1 shared publication- Maria Robu
Department of Hematology, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova
1 shared publication - Natalia Sporis
Department of Hematology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
1 shared publication - Sanda Buruiana
Department of Hematology, Nicolae Testemitanu University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova
1 shared publication
Latest Publications
- 16 June 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26, 1-12
Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets
Introduction/Background: Therapy-Induced Senescence (TIS) is increasingly recognized as a clinically relevant outcome of anticancer therapy, particularly after suble-thal genotoxic stress. In Non-Hodgkin Lymphomas (NHL), TIS may coexist with apopto-sis and contribute to treatment heterogeneity by enabling the long-term survival of dam-aged but viable tumor cells. The aim of this article is to synthesize the core molecular mechanisms of TIS in NHL, and to highlight druggable senolytic and senomorphic strate-gies that may improve disease control and reduce the risk of relapse. Material and Methods: A narrative review was conducted using mechanistic and translational literature addressing DNA Damage Response (DDR) signaling, p53-p21 and p16^INK4a^-RB checkpoint pathways, Senescence-Associated Secretory Phenotype (SASP), epigenetic remodeling, senescence escape, stemness acquisition, and therapeutic targeting of senescent tumor cells. Searches were performed in PubMed / MEDLINE, Scopus, and Google Scholar using combinations of the terms “therapy-induced senes-cence”, “cellular senescence”, “SASP”, “senolytic”, “senomorphic”, and “senescence es-cape”. Priority was given to studies published between 2010 and 2026, while older land-mark studies were included when mechanistically essential. Results: TIS is initiated by persistent DDR signaling (ATM/ATR→CHK1/CHK2) with downstream activation of p53-p21 and/or p16^INK4a^-RB pathways, resulting in stable growth arrest. Senescent lymphoma cells may acquire a SASP that remodels the tumor microenvironment and modulates immune responses. Epigenetic reprogramming (e.g., SAHF formation, H3K9me3 dynamics, lamin B1 loss) supports phenotypic plasticity and may enable escape from senescence with stem-like features, contributing to residual dis-ease persistence and relapse biology. Discussion: Therapeutically, senolytic approaches (e.g., BH3 mimetics, BCL-2/BCL-xL antagonists) and senomorphic strategies (targeting SASP regulators such as NF-κB, JAK/STAT, and mTOR) represent potentially actionable therapeutic approaches. Emerging senolytic Chimeric Antigen Receptor T-cell (CAR-T cell) strategies targeting senescence-associated surface programs, such as uPAR, further expand the therapeutic landscape, although these approaches remain at a preclinical stage at the time of writing this review. Conclusion: In lymphomas, TIS is a dynamic stress-adaptation state that can support persistence and relapse. Rational integration of senescence biomarkers, timing-based therapies, and targeted senolytic/senomorphic interventions may enhance long-term treatment efficacy; however, most senescence-targeted strategies remain investigational and require lymphoma-specific clinical validation.
- 16 June 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26, 1-12
Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets
Introduction/Background: Therapy-Induced Senescence (TIS) is increasingly recognized as a clinically relevant outcome of anticancer therapy, particularly after suble-thal genotoxic stress. In Non-Hodgkin Lymphomas (NHL), TIS may coexist with apopto-sis and contribute to treatment heterogeneity by enabling the long-term survival of dam-aged but viable tumor cells. The aim of this article is to synthesize the core molecular mechanisms of TIS in NHL, and to highlight druggable senolytic and senomorphic strate-gies that may improve disease control and reduce the risk of relapse. Material and Methods: A narrative review was conducted using mechanistic and translational literature addressing DNA Damage Response (DDR) signaling, p53-p21 and p16^INK4a^-RB checkpoint pathways, Senescence-Associated Secretory Phenotype (SASP), epigenetic remodeling, senescence escape, stemness acquisition, and therapeutic targeting of senescent tumor cells. Searches were performed in PubMed / MEDLINE, Scopus, and Google Scholar using combinations of the terms “therapy-induced senes-cence”, “cellular senescence”, “SASP”, “senolytic”, “senomorphic”, and “senescence es-cape”. Priority was given to studies published between 2010 and 2026, while older land-mark studies were included when mechanistically essential. Results: TIS is initiated by persistent DDR signaling (ATM/ATR→CHK1/CHK2) with downstream activation of p53-p21 and/or p16^INK4a^-RB pathways, resulting in stable growth arrest. Senescent lymphoma cells may acquire a SASP that remodels the tumor microenvironment and modulates immune responses. Epigenetic reprogramming (e.g., SAHF formation, H3K9me3 dynamics, lamin B1 loss) supports phenotypic plasticity and may enable escape from senescence with stem-like features, contributing to residual dis-ease persistence and relapse biology. Discussion: Therapeutically, senolytic approaches (e.g., BH3 mimetics, BCL-2/BCL-xL antagonists) and senomorphic strategies (targeting SASP regulators such as NF-κB, JAK/STAT, and mTOR) represent potentially actionable therapeutic approaches. Emerging senolytic Chimeric Antigen Receptor T-cell (CAR-T cell) strategies targeting senescence-associated surface programs, such as uPAR, further expand the therapeutic landscape, although these approaches remain at a preclinical stage at the time of writing this review. Conclusion: In lymphomas, TIS is a dynamic stress-adaptation state that can support persistence and relapse. Rational integration of senescence biomarkers, timing-based therapies, and targeted senolytic/senomorphic interventions may enhance long-term treatment efficacy; however, most senescence-targeted strategies remain investigational and require lymphoma-specific clinical validation.